<DOC>
	<DOC>NCT00307593</DOC>
	<brief_summary>The purpose of this study is to compare a 2 immunosuppressant regimen for the treatment of relapsing or refractory necrotizing antineutrophil cytoplasmic antibody (ANCA) associated vasculitides.</brief_summary>
	<brief_title>RATTRAP: Infliximab Versus Rituximab in Systemic Necrotizing Vasculitides</brief_title>
	<detailed_description>The aim of this study is to compare the efficacy of rituximab versus infliximab in relapsing or refractory forms of ANCA+ vasculitides (Microscopic Polyangiitis, Wegener's granulomatosis and Churg-Strauss syndrome).</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Granulomatosis with Polyangiitis</mesh_term>
	<mesh_term>Systemic Vasculitis</mesh_term>
	<mesh_term>Churg-Strauss Syndrome</mesh_term>
	<mesh_term>Microscopic Polyangiitis</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<criteria>Systemic ANCA positive (+) vasculitides Relapsing or refractory vasculitides, resistant to corticosteroids and reference immunosuppressant therapies Age &gt;18 years old Written informed consent Newly diagnosed patient Patient that had never received an immunosuppressant before to treat his/her vasculitis Malignancy Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Systemic ANCA+ vascularizes</keyword>
	<keyword>Relapse</keyword>
	<keyword>Corticosteroids</keyword>
	<keyword>Immunosuppressant</keyword>
	<keyword>Infliximab/rituximab</keyword>
	<keyword>Patients with relapsing or refractory forms of ANCA</keyword>
	<keyword>associated vasculitides Microscopic polyangiitis</keyword>
</DOC>